Shattuck Labs (STTK) Competitors

Shattuck Labs (NASDAQ:STTK) and Inhibrx (NASDAQ:INBX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, community ranking, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Do institutionals and insiders believe in STTK or INBX?

58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 82.5% of Inhibrx shares are held by institutional investors. 10.5% of Shattuck Labs shares are held by company insiders. Comparatively, 22.2% of Inhibrx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Does the media favor STTK or INBX?

In the previous week, Inhibrx had 3 more articles in the media than Shattuck Labs. MarketBeat recorded 3 mentions for Inhibrx and 0 mentions for Shattuck Labs. Inhibrx's average media sentiment score of 0.54 beat Shattuck Labs' score of 0.00 indicating that Inhibrx is being referred to more favorably in the news media.

Company	Overall Sentiment
Shattuck Labs	Neutral
Inhibrx	Positive

Is STTK or INBX more profitable?

Inhibrx has a net margin of 0.00% compared to Shattuck Labs' net margin of -1,156.46%. Shattuck Labs' return on equity of -61.92% beat Inhibrx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	-1,156.46%	-61.92%	-54.49%
Inhibrx	N/A	-113.74%	-80.56%

Which has preferable valuation and earnings, STTK or INBX?

Shattuck Labs has higher revenue and earnings than Inhibrx.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$6.44M	8.53	-$87.30M	-$1.53	-0.75
Inhibrx	$1.57M	134.79	-$154.96M	N/A	N/A

Does the MarketBeat Community favor STTK or INBX?

Shattuck Labs received 6 more outperform votes than Inhibrx when rated by MarketBeat users. Likewise, 71.15% of users gave Shattuck Labs an outperform vote while only 59.62% of users gave Inhibrx an outperform vote.

Company	Underperform	Outperform
Shattuck Labs	Outperform Votes 37 71.15%	Underperform Votes 15 28.85%
Inhibrx	Outperform Votes 31 59.62%	Underperform Votes 21 40.38%

Do analysts rate STTK or INBX?

Shattuck Labs presently has a consensus price target of $8.67, indicating a potential upside of 653.62%. Given Shattuck Labs' stronger consensus rating and higher probable upside, analysts plainly believe Shattuck Labs is more favorable than Inhibrx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.40
Inhibrx	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Shattuck Labs beats Inhibrx on 9 of the 15 factors compared between the two stocks.